| Literature DB >> 31377122 |
Takashi Ogura1, Nagio Takigawa2, Keisuke Tomii3, Kazuma Kishi4, Yoshikazu Inoue5, Eiki Ichihara6, Sakae Homma7, Kazuhisa Takahashi8, Hiroaki Akamatsu9, Satoshi Ikeda1, Naohiko Inase10, Tae Iwasawa11, Yuichiro Ohe12, Hiromitsu Ohta13, Hiroshi Onishi14, Isamu Okamoto15, Kazumasa Ogawa4, Kazuo Kasahara16, Hiroki Karata17, Takumi Kishimoto18, Yuka Kitamura17, Akihiko Gemma19, Hirotsugu Kenmotsu20, Hiroyuki Sakashita10, Susumu Sakamoto7, Katsutoshi Sekine21, Yuichi Takiguchi22, Yuji Tada23, Shinichi Toyooka24, Yuko Nakayama25, Yasuhiko Nishioka26, Koichi Hagiwara27, Masaki Hanibuchi28, Junya Fukuoka17, Yuji Minegishi19, Toyoshi Yanagihara15, Nobuyuki Yamamoto9, Hiromasa Yamamoto24, Mina Gaga29, Kwun M Fong30, Charles A Powell31, Katsuyuki Kiura32.
Abstract
Dramatic progress in targeted therapy and immunotherapy has been changing clinical practices in lung cancer. With the accumulation of clinical practice, it has become clear that pre-existing interstitial pneumonia (IP) could be a risk factor for drug-induced lung injury, which has enhanced awareness regarding the difficulty in treating lung cancer with comorbid IP. Unfortunately, there is only low-grade evidence in the field of lung cancer with comorbid IP, because almost all clinical trials exclude such patients. There have been very few specialized clinical trials for patients with lung cancer and underlying IPs thus far. Therefore, it is necessary to treat such cases empirically or to give up on the treatment itself. Considering these circumstances, establishing how to treat lung cancer with comorbid IP is an urgent issue. This paper is a summary of the official statement reported by the Diffuse Lung Disease/Thoracic Oncology Assembly and the Japanese Respiratory Society (JRS) in 2017, which attempts to approach lung cancer with comorbid IP systematically.Entities:
Year: 2019 PMID： 31377122 DOI： 10.1016/j.resinv.2019.06.001
Source DB: PubMed Journal: Respir Investig ISSN： 2212-5345